Your session is about to expire
← Back to Search
recombinant human annexin A5 for Coronavirus (AX-COVID Trial)
AX-COVID Trial Summary
This trial is testing a potential new treatment for severe coronavirus disease. It is comparing SY-005 (a recombinant human Annexin A5) to a placebo to see if it is effective. The trial is double-blind, meaning that neither the patients nor the doctors know who is receiving the SY-005 or the placebo.
- Coronavirus
- Sepsis
AX-COVID Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAX-COVID Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AX-COVID Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has recombinant human annexin A5 received FDA approval yet?
"While there is limited data on recombinant human annexin A5's efficacy, what evidence exists suggest it is safe."
To date, how many individuals have opted into this clinical trial?
"That is correct, the clinical trial is still actively recruiting patients. The first posting was on April 20th 2021 with the most recent update occurring on April 23rd of this year. They are looking for a total of 60 individuals across a single site."
What are the goals of this experiment?
"The 12-month study will focus on Protocol adherence, with secondary objectives being to track the number of patients with organ dysfunction and ventilator usage."
Are there any current vacancies for patients in this clinical trial?
"The clinicaltrials.gov website shows that this study is still recruiting patients. It was originally posted on 4/20/2021, with the most recent update being from 4/23/2021."
Share this study with friends
Copy Link
Messenger